1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Qiagen N.V.
  6. News
  7. Summary
    QGEN   NL0012169213


Real-time Estimate Cboe BZX  -  05/19 01:51:23 pm EDT
44.64 USD   +1.54%
05/16QIAGEN NV : Berenberg keeps its Buy rating
05/16QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
05/16QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Qiagen N : liquid-based sample-prep-and-detection kit helps labs ramp up COVID testing capacity by slashing processing times

01/13/2022 | 09:41am EDT
  • artus® SARS-CoV-2 Prep&Amp UM cuts PCR processing times by two thirds
  • Kit reliably detects SARS-CoV-2 infections with Omicron variant on all PCR instruments
  • QIAseq DIRECT SARS-CoV-2 Kit allows labs to dramatically increase sequencing

Hilden, Germany, and Germantown, Maryland, January 13, 2022 - QIAGEN today announced it is working with genetic laboratories around the world to increase COVID-19 testing capacity with its artus® SARS-CoV-2 Prep&Amp UM Kit that uses liquid-based sample-preparation technology to cut processing times for PCR results by up to two thirds. The company has significantly expanded production capacities to be able to meet the growing testing demand spurred by the emergence of the new Omicron variant.

Integrating sample preparation and detection into a single kit, artus® SARS-CoV-2 Prep&Amp UM enables labs to analyze samples in one hour - rather than the three hours typically required by standard extraction-based real-time PCR processes. The kit is compatible with all PCR machines and can support up to 672 samples being analyzed by one thermal cycler in one eight-hour shift.

"Since we started using this QIAGEN kit, we have been able to triple our PCR capacity to test for SARS-CoV-2," said Ludwig Knabl, medical head of the molecular biological laboratory of Tyrolpath Obrist Brunhuber GmbH. "artus® SARS-CoV-2 Prep&Amp UM is faster than standard processes and can detect the virus just as reliably, including the new Omicron variant. The kit's simple workflow accelerates turnaround and reduces the workload of our lab technicians."

QIAGEN's artus® SARS-CoV-2 Prep&Amp UM Kit has been CE-IVD registered for clinical use in the European Union and other markets and is available for research use in the United States. The kit combines liquid-based sample preparation - which takes no more than two minutes - with a real-time PCR assay. It comes with all the reagents required for sample-to-result testing of samples. The test is validated for different types of swabs as well as for crude saliva in asymptomatic and symptomatic patient populations.

"Our artus SARS-COV-2 Prep&AMP has been gaining significant traction in the market in times of surging global testing demand. Its novel sample-preparation technology enables laboratories to ramp up PCR-testing capacity using their existing infrastructure - a crucial factor as the Omicron variant of SARS-CoV-2 spreads quickly," said Kai te Kaat, Vice President, Program Lead Life Sciences Business Area at QIAGEN. "Having significantly expanded our production capacity, we are confident we will be able to satisfy surging demand from PCR labs."

QIAGEN is also helping laboratories develop a more comprehensive picture of circulating SARS-CoV-2 variants by enabling them to dramatically increase genomic surveillance using next-generation sequencing (NGS). The new enhanced QIAseq DIRECT SARS-CoV-2 Kit modifies the existing workflow to provide higher coverage and uniformity and requires less sequencing reads, allowing researchers to more quickly and easily identify and distinguish between multiple circulating Variants of Concern, (including the Omicron and Delta variants) even in samples with very low SARS-CoV-2 concentration.

More information on artus® SARS-CoV-2 Prep&Amp UM Kit can be found here.

More information on QIAseq DIRECT SARS-CoV-2 Kit can be found here.

For an overview of QIAGEN's coronavirus testing solutions, please visit http://www.qiagen.com/coronavirus.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2020, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Qiagen NV published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 14:40:09 UTC.

© Publicnow 2022
All news about QIAGEN N.V.
05/16QIAGEN NV : Berenberg keeps its Buy rating
05/16QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-D..
05/16QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-D..
05/11SECTOR UPDATE : Health Care Stocks Edging Lower Ahead of Wednesday Close
05/11SECTOR UPDATE : Health Care Stocks Still Hanging on for Small Advance
05/11Qiagen to Acquire 96% Stake In BLIRT for Undisclosed Sum
05/11QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
05/11QIAGEN Proposes Expansion of Supervisory Board
05/11Qiagen N.V. agreed to acquire 96.3% stake in BLIRT S.A. from N50 Cyprus Limited, Marian..
05/10TRANSCRIPT : QIAGEN N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-20..
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2022 2 093 M - -
Net income 2022 387 M - -
Net Debt 2022 497 M - -
P/E ratio 2022 25,7x
Yield 2022 -
Capitalization 9 999 M 9 999 M -
EV / Sales 2022 5,02x
EV / Sales 2023 4,69x
Nbr of Employees 6 000
Free-Float 98,2%
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 43,96 $
Average target price 56,32 $
Spread / Average Target 28,1%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Vice President-Finance
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Lezette Young Manager-Compliance & Legal
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-20.91%9 999
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323